On May 27, Duality Biotherapeutics-B rose 5.36% in regular trading, trading at HK$228.2/share, with trading volume of HK$112 million.

On the news front, the company executed an open-market share repurchase of 30,000 shares on May 26, spending approximately HK$6.5144 million at prices ranging from HK$216.20 to HK$218.40 per share. The repurchased shares will be held as treasury stock. This buyback marks the initial execution of the companys previously announced plan to repurchase up to US$40 million in shares. Meanwhile, LAV Asset Management increased its holdings by 105,000 shares on May 20 at an average price of approximately HK$226.09 per share, totaling around HK$23.79 million, raising its stake to 13.00%.

The stock had previously declined over 18% from approximately HK$257 to HK$210.4 following the May 12 announcement that the company exercised its US market cost and profit/loss sharing option for DB-1311/BNT324 with BioNTech, which raised short-term funding concerns. The combination of buyback execution, founder commitment to purchase up to US$5 million in shares, and institutional accumulation has helped restore market confidence.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)